Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on January 16, 2025, announcing a significant development in pending shareholder derivative actions. The report details that on January 8, 2025, the United States District Court for the District of Massachusetts granted preliminary approval to a proposed settlement concerning two shareholder derivative lawsuits and demands for company records. These actions are directly related to the prior recall and retirement of the LOTUS Edge™ Aortic Valve System. The proposed settlement, agreed upon by various parties including the company and named defendants, is now subject to final court approval. A hearing for this final approval is scheduled for March 25, 2025. Investors should monitor this date as it will determine the final resolution of these legal matters and any potential implications for the company.
Key Highlights
- 1Preliminary court approval granted for a settlement of shareholder derivative actions.
- 2The lawsuits are related to the recall and retirement of the LOTUS Edge™ Aortic Valve System.
- 3A final court approval hearing is scheduled for March 25, 2025.
- 4The company is filing the Stipulation of Settlement and Notice of Proposed Derivative Settlement as exhibits.
- 5This filing indicates a potential resolution to ongoing legal proceedings stemming from a past product issue.